Amgen (AMGN) Expected to Announce Quarterly Earnings on Thursday

Amgen (NASDAQ:AMGN) is expected to be issuing its Q1 2025 quarterly earnings data after the market closes on Thursday, May 1st. Analysts expect Amgen to post earnings of $4.18 per share and revenue of $8.05 billion for the quarter. Amgen has set its FY 2025 guidance at 20.000-21.200 EPS.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. On average, analysts expect Amgen to post $21 EPS for the current fiscal year and $21 EPS for the next fiscal year.

Amgen Price Performance

NASDAQ AMGN opened at $283.09 on Tuesday. Amgen has a fifty-two week low of $253.30 and a fifty-two week high of $346.85. The stock’s 50-day moving average is $301.29 and its two-hundred day moving average is $292.11. The company has a debt-to-equity ratio of 9.62, a current ratio of 1.26 and a quick ratio of 0.95. The firm has a market cap of $152.20 billion, a P/E ratio of 37.50, a price-to-earnings-growth ratio of 2.63 and a beta of 0.59.

Amgen Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Friday, May 16th will be issued a dividend of $2.38 per share. The ex-dividend date of this dividend is Friday, May 16th. This represents a $9.52 annualized dividend and a yield of 3.36%. Amgen’s dividend payout ratio (DPR) is currently 126.09%.

Insider Activity

In other news, SVP Nancy A. Grygiel sold 1,589 shares of the firm’s stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $304.47, for a total value of $483,802.83. Following the completion of the sale, the senior vice president now directly owns 7,210 shares in the company, valued at approximately $2,195,228.70. This trade represents a 18.06 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP David M. Reese sold 25,225 shares of the firm’s stock in a transaction on Friday, February 21st. The shares were sold at an average price of $304.44, for a total value of $7,679,499.00. Following the completion of the sale, the executive vice president now owns 36,922 shares of the company’s stock, valued at approximately $11,240,533.68. This trade represents a 40.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 69,341 shares of company stock worth $20,644,335. Company insiders own 0.69% of the company’s stock.

Institutional Trading of Amgen

An institutional investor recently raised its position in Amgen stock. Brighton Jones LLC grew its holdings in Amgen Inc. (NASDAQ:AMGN) by 23.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 27,468 shares of the medical research company’s stock after buying an additional 5,226 shares during the quarter. Brighton Jones LLC’s holdings in Amgen were worth $7,159,000 at the end of the most recent reporting period. 76.50% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research firms have weighed in on AMGN. StockNews.com lowered Amgen from a “strong-buy” rating to a “buy” rating in a report on Thursday, April 17th. Morgan Stanley lifted their price objective on Amgen from $328.00 to $330.00 and gave the stock an “equal weight” rating in a research note on Wednesday, April 9th. Piper Sandler Companies reissued an “overweight” rating and set a $310.00 price objective on shares of Amgen in a research report on Thursday, January 2nd. Cantor Fitzgerald assumed coverage on Amgen in a research report on Tuesday, April 22nd. They set a “neutral” rating and a $305.00 price objective for the company. Finally, Truist Financial cut their price objective on Amgen from $333.00 to $298.00 and set a “hold” rating for the company in a research report on Wednesday, January 8th. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $310.57.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.